Autoimmune gastrointestinal dysmotility: Difference between revisions
Librariannx (talk | contribs) m Added two sentences about treatments not already mentioned. #citeNLM2018 |
Librariannx (talk | contribs) →Treatment: Added links. #citeNLM2018 |
||
| Line 9: | Line 9: | ||
== Treatment == |
== Treatment == |
||
Medications to relieve nausea and vomiting or to enhance mobility may be helpful, as may cholinesterase inhibitors. Immunotherapy and plasma exchange have also been reportedly effective.<ref>{{Cite web|url=https://rarediseases.info.nih.gov/diseases/12063/autoimmune-gastrointestinal-dysmotility|title=Autoimmune gastrointestinal dysmotility {{!}} Genetic and Rare Diseases Information Center (GARD) – an NCATS Program|website=rarediseases.info.nih.gov|language=en|access-date=2018-04-17}}</ref> [[Pyridostigmine]] is a pharmaceutical treatment option for patients with AGID.<ref name="ncbi" /> |
Medications to relieve nausea and vomiting or to enhance mobility may be helpful, as may [[Acetylcholinesterase inhibitor|cholinesterase inhibitors]]. [[Immunotherapy]] and [[Plasmapheresis|plasma exchange]] have also been reportedly effective.<ref>{{Cite web|url=https://rarediseases.info.nih.gov/diseases/12063/autoimmune-gastrointestinal-dysmotility|title=Autoimmune gastrointestinal dysmotility {{!}} Genetic and Rare Diseases Information Center (GARD) – an NCATS Program|website=rarediseases.info.nih.gov|language=en|access-date=2018-04-17}}</ref> [[Pyridostigmine]] is a pharmaceutical treatment option for patients with AGID.<ref name="ncbi" /> |
||
In severe cases patients with AGID are required to abandon eating foods, requiring them to get nourishment through a process called [[parenteral nutrition]], where the patient is fed via a permanent [[Intravenous therapy|IV]] and the liquid [[nourishment]] is infused directly in the blood stream, as opposed to a feeding tube. |
In severe cases patients with AGID are required to abandon eating foods, requiring them to get nourishment through a process called [[parenteral nutrition]], where the patient is fed via a permanent [[Intravenous therapy|IV]] and the liquid [[nourishment]] is infused directly in the blood stream, as opposed to a feeding tube. |
||
Revision as of 17:38, 17 April 2018
Autoimmune gastrointestinal dysmotility (AGID) is an autoimmune disease autonomic neuropathy affecting the gastrointestinal organs and digestive system of the body. Dysmotility is when the strength or coordination of the esophagus, stomach or intestines muscles do not work as they should.[1]
Diagnosis
AGID is diagnosed with a complete medical history, exam of patients motility and with special blood tests looking for autoantibodies consistent with neurologic autoimmunity.[2] Blood tests included evaluations of immunofluorescence (neuronal nuclear and cytoplasmic antibodies), radioimmunoprecipitation assays (neuronal and muscle plasma membrane cation channel antibodies), and enzyme-linked immunosorbent assay (muscle striational antibodies). A finding, along with medical history, of ganglionic neuronal acetylcholine receptor and N-type voltage-gated calcium channel autoantibodies in the blood stream would result in a medically acceptable diagnosis of AGID.[3]
Common illnesses
Often AGID is a symptom of other problems, including colon cancer, lupus, lung, breast, or ovarian carcinoma or thymoma. or other diseases. Irritable bowel syndrome (IBS) is the most recognized form of AGID[citation needed].
Treatment
Medications to relieve nausea and vomiting or to enhance mobility may be helpful, as may cholinesterase inhibitors. Immunotherapy and plasma exchange have also been reportedly effective.[4] Pyridostigmine is a pharmaceutical treatment option for patients with AGID.[3] In severe cases patients with AGID are required to abandon eating foods, requiring them to get nourishment through a process called parenteral nutrition, where the patient is fed via a permanent IV and the liquid nourishment is infused directly in the blood stream, as opposed to a feeding tube.
References
- ^ Bolen, Barbara Bradley. "Dysmotility". About.com. Retrieved 14 January 2013.
- ^ Dhamija, Radhika; Tan, K. Meng; Pittock, Sean J.; Foxx–Orenstein, Amy; Benarroch, Eduardo; Lennon, Vanda A. (2008). "Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal Dysmotility". Clinical Gastroenterology and Hepatology. 6 (9): 988–92. doi:10.1016/j.cgh.2008.04.009. PMC 2741093. PMID 18599359.
- ^ a b Pasha, Shabana F.; Lunsford, Tisha N.; Lennon, Vanda A. (2006). "Autoimmune Gastrointestinal Dysmotility Treated Successfully with Pyridostigmine". Gastroenterology. 131 (5): 1592–6. doi:10.1053/j.gastro.2006.06.018. PMID 17101331.
- ^ "Autoimmune gastrointestinal dysmotility | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2018-04-17.
External links
- "Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation". Mayo Medical Laboratories.